



1/14


[Fig. 1]



2/14
[Fig. 2]




[Fig. 3]




4/14

[Fig. 4]




5/14


[Fig. 5]




6/14
[Fig. 6]
A



B




7/14
[Fig. 7]




8/14

[Fig. 8]




[Fig. 9]




9/14

[Fig. 10]




10/14

[Fig. 11]



11/14

[Fig. 12]




Antibodies legend:

In figure	In patent text
B5	Antibody 1 (SS6V1-B5)
E7	Antibody 11 (SS6V11-E7)
E11	Antibody 12 (SS6V12-E11)
F1	Antibody 13 (SS6V13-F1)
F4	Antibody 19 (SS6V19-F4)
F5	Antibody 20 (SS6V20-F5)

12/14

[Fig. 13]




Antibodies legend:

In figure	In patent text
B5	Antibody 1 (SS6V1-B5)
E7	Antibody 11 (SS6V11-E7)
E11	Antibody 12 (SS6V12-E11)
F1	Antibody 13 (SS6V13-F1)
F4	Antibody 19 (SS6V19-F4)
F5	Antibody 20 (SS6V20-F5)

13/14

[Fig. 14]




Antibodies legend:

In figure	In patent text
B5	Antibody 1 (SS6V1-B5)
E7	Antibody 11 (SS6V11-E7)
E11	Antibody 12 (SS6V12-E11)
F1	Antibody 13 (SS6V13-F1)
F4	Antibody 19 (SS6V19-F4)
F5	Antibody 20 (SS6V20-F5)


14/14

[Fig. 15]

A



B



C

mAb	End-point VNT (ng/ml)		
	D614G	Omicron BA.1	Omicron BA.2
E7	≤ 62.5	≤ 62.5	500
F1	≤ 62.5	125	2000
F5	≤ 62.5	≤ 62.5	2000
S309	≤ 62.5	1000	> 2000
CR3022	2000	> 2000	> 2000
S2X259	125	2000	Not done

Antibodies legend:

In figure	In patent text
E7	Antibody 11 (SS6V11-E7)
F1	Antibody 13 (SS6V13-F1)
F5	Antibody 20 (SS6V20-F5)